Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Denisa Muraru Added: 2 weeks ago
Discover why tricuspid regurgitation aetiology matters for patient outcomes and intervention strategies with Prof Denisa MuraruThis presentation, part of a comprehensive series on complex cases in interventional cardiology, explores how understanding TR mechanisms directly impacts diagnosis, treatment selection, and clinical prognosis.Prof Muraru addresses the critical heterogeneity in TR… View more
Author(s): Alfonso Ielasi Added: 1 year ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more
Author(s): Jonathon A Leipsic Added: 2 years ago
FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).A 14%… View more
Author(s): Added: 6 months ago
New York Valves 25 - Quantitative findings from Tri-QOL showed a strong correlation between tricuspid regurgitation (TR) reduction and KCCQ improvement after transcatheter tricuspid valve intervention (TTVI).Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, Kansas City, US) discusses findings from a quantitative analysis from the Tri-QOL study which aimed to assess the optimal result… View more
Author(s): Marianne Brodmann Added: 4 months ago
CIRSE Congress 2025 - 24-month results show the Biotronik Dynetic-35 cobalt chromium balloon-expandable stent was safe and effective in iliac arteries.Prof Marianne Brodmann (Medical University of Graz, Graz, AT) joins us to discuss 24-month findings from BIONETIC-I (NCT04830228). The prospective, international, multi-center, single-arm study aimed to investigate the safety and effectiveness of… View more
Author(s): Santiago Garcia Added: 6 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings… View more
Author(s): Michelle O'Donoghue Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to… View more
Author(s): Julien Dreyfus Added: 8 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating… View more